WASHINGTON, D.C. (May 15, 2023) – The Association for Accessible Medicines Interim CEO, David Gaugh, today released the following statement regarding the U.S. Supreme Court's decision to decline hearing the GSK v. Teva case:
"AAM is disappointed that the U.S. Supreme Court denied certiorari in the GSK v. Teva case. AAM will continue to support the Hatch-Waxman framework which expressly contemplates prompt generic drug availability through patent carve-outs, also known as skinny labeling."
MEDIA CONTACT:
Susan Reilly
Director of Communications, AAM
1.703.725.0729
About AAM
AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 91 percent of prescriptions dispensed in the U.S. but only 18 percent of total drug spending.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.